This is indeed very good news. It means we now have both of our drug candidates (IRX211 -pain and IRX616 -panic) underway in terms of the establishment of their respective clinical trials.
It takes a couple of months to do all the preparatory work to dose patients in the trials with all the relevant spec adjustment, stability work and finally batch manufacturing. Batch manufacturing should be now underway for both 616 and 211 in the next 2-3 months with dosing occurring immediately after. I would expect patient enrolment and screening to occur in parallel with manufacturing so FPFD for both trials early Q3.
The announcement today states that we should race straight to our Phase 2 616 trial in 2025 as well so that implies that the Phase 1 will be very short and sharp and move straight into testing efficacy. We know 211 is front running 616.
You cant book a slot for batch manufacturing without a payment, so i assume this might mean that the first drawdowns from the Clendon finance facility may well have occurred.
Gee it really is getting exciting. I feel like we are finally on the verge of a seriously exciting phase of this company!
Add to My Watchlist
What is My Watchlist?
